AG Tumorantigen-Entdeckung & Translationale Immuntherapie

Leitung

Prof. Dr. Bastian Schilling

Wissenschaftliche Mitarbeiter(innen)

Dr. Andreas Schlosser
Dr. Melissa Bernhardt

(Medizinisch)-Technische Assistent(innen)

Stephanie Hoffmann
Tsige Hailemariam-Jahn
Veronika König

Unsere Publikationen

Weller, C., Bartok, O., McGinnis, C. S., Palashati, H., Chang, T. G., Malko, D., Shmueli, M. D., Nagao, A., Hayoun, D., Murayama, A., Sakaguchi, Y., Poulis, P., Khatib, A., Erlanger Avigdor, B., Gordon, S., Cohen Shvefel, S., Zemanek, M. J., Nielsen, M. M., Boura-Halfon, S., …,Schlosser, A., Samuels, Y. (2025). Translation dysregulation in cancer as a source for targetable antigens. Cancer Cell, 43(5), 823-840.e18. doi.org/10.1016/j.ccell.2025.03.003

He, M., Bernhardt, M., Arakawa, A., Kim, S. M., Vollmer, S., Summer, B., Arakawa, Y., Ishimoto, T., Schlosser, A., & Prinz, J. C. (2025). B Cells Can Trigger the T-Cell-Mediated Autoimmune Response Against Melanocytes in Psoriasis. Cells, 14(24). doi.org/10.3390/cells14242002

Bernhardt, M., Rech, A., Berthold, M., Lappe, M., Herbel, J.-N., Erhard, F., Paschen, A., Schilling, B., & Schlosser, A. (2025). SILAC-based quantification reveals modulation of the immunopeptidome in BRAF and MEK inhibitor sensitive and resistant melanoma cells. Frontiers in Immunology, 15. doi.org/10.3389/fimmu.2024.1490821

Wohlfarth, J., Kosnopfel, C., Faber, D., Berthold, M., Siedel, C., Bernhardt, M., Schlosser, A., Aprati, T., Liu, D., Schrama, D., Houben, R., Schadendorf, D., Goebeler, M., Meierjohann, S., & Schilling, B. (2024). Loss of p14 diminishes immunogenicity in melanoma via non-canonical Wnt signaling by reducing the peptide surface density. Molecular Oncology. doi.org/10.1002/1878-0261.13660

Lozano-Rabella, M., Garcia-Garijo, A., Palomero, J., Yuste-Estevanez, A., Erhard, F., Farriol-Duran, R., Martín-Liberal, J., Ochoa-De-Olza, M., Matos, I., Gartner, J. J., Ghosh, M., Canals, F., Vidal, A., Piulats, J. M., Matías-Guiu, X., Brana, I., Muñoz-Couselo, E., Garralda, E., Schlosser, A., & Gros, A. (2023). Exploring the Immunogenicity of Noncanonical HLA-I Tumor Ligands Identified through Proteogenomics. Clinical Cancer Research, 29(12), 2250–2265. doi.org/10.1158/1078-0432.CCR-22-3298

Bernhardt, M., Cruz-Garcia, Y., Rech, A., Meierjohann, S., Erhard, F., Schilling, B., & Schlosser, A. (2022). Extending the Mass Spectrometry-Detectable Landscape of MHC Peptides by Use of Restricted Access Material. Analytical Chemistry, 94(41), 14214–14222. doi.org/10.1021/acs.analchem.2c02198

Marcu, A., Bichmann, L., Kuchenbecker, L., Kowalewski, D. J., Freudenmann, L. K., Backert, L., Mühlenbruch, L., Szolek, A., Lübke, M., Wagner, P., Engler, T., Matovina, S., Wang, J., Hauri-Hohl, M., Martin, R., Kapolou, K., Walz, J. S., Velz, J., Moch, H., … Neidert, M. C. (2021). HLA Ligand Atlas: A benign reference of HLA-presented peptides to improve T-cell-based cancer immunotherapy. Journal for ImmunoTherapy of Cancer, 9(4). doi.org/10.1136/jitc-2020-002071

Erhard, F., Dölken, L., Schilling, B., & Schlosser, A. (2020). Identification of the cryptic HLA-I immunopeptidome. Cancer Immunology Research, 8(8), 1018–1026. doi.org/10.1158/2326-6066.CIR-19-0886